Latest Press Releases
19 June 2025
“Eisai is deeply concerned by the NICE decision announced today and very upset by what it means for people with Alzheimer’s disease and their families in England, now and in the future. We call for urgent Government action on NHS readiness to tackle this condition and an immediate overhaul of the NICE appraisal process for early Alzheimer’s disease medicines.”
pdf - 225 KB
30 April 2025
Leqembi®▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA
pdf - 174 KB
16 April 2025
Leqembi®▼ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorised in the European Union
pdf - 233 KB
6 March 2025
Leqembi®▼ (lecanemab) enters second consultation period following NICE draft guidance update
pdf - 189 KB
14 November 2024
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
pdf - 224 KB
22 August 2024
